NCT04006301View on ClinicalTrials.gov

First-in-Human Study of JNJ-74699157 in Participants With Tumors Harboring the KRAS G12C Mutation

PHASE1CompletedINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

July 26, 2019

Primary Completion Date

July 13, 2020

Study Completion Date

July 13, 2020

Conditions
NeoplasmsAdvanced Solid TumorsNon-small Cell Lung CancerColorectal Cancer
Interventions
DRUG

JNJ-74699157

Participants will receive JNJ-74699157 orally.

Trial Locations (7)

13885

Hopital de la Timone, Marseille

33612

H. Lee Moffitt Cancer & Research Institute, Tampa

34232

Florida Cancer Specialists, Sarasota

37203

Sarah Cannon Research Institute, Nashville

69373

Centre Leon Bérard, Lyon

78229

NEXT Oncology, San Antonio

94800

Institut Gustave Roussy, Villejuif

All Listed Sponsors
lead

Janssen Research & Development, LLC

INDUSTRY

NCT04006301 - First-in-Human Study of JNJ-74699157 in Participants With Tumors Harboring the KRAS G12C Mutation | Biotech Hunter | Biotech Hunter